Overall verdict
Sell
3.1/10
1-year performance
+800.65%
Score breakdown
Up 800.7% over 1 year, 82% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Shareholder return 0.0/10.
23 analysts, target -0.3% vs the price.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine ; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines ; enteric viruses include norovirus ;
public health vaccines consist of Zika, Nipah, and Mpox vaccines ; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc ;
Vertex Pharmaceuticals Incorporated ; Vertex Pharmaceuticals (Europe) Limited ; immatics N.V. ; Defense Advanced Research Projects Agency ; Biomedical Advanced Research and Development Authority ; Institute for Life Changing Medicines ; The Bill & Melinda Gates Foundation ; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Stéphane Bancel
Founded
2010
Employees
4 700
Revenue / employee
413 617 USD
Next earnings
February 11, 2027 (estimated)
Institutional holders
- FMR LLC14.57%
- GEODE CAPITAL MANAGEMENT, LLC2.53%
- Bank of New York Mellon Corp0.42%
- Rest of the register82.48%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
280.80 USD
52-week low
22.28 USD
1-year performance
800.65%
Rising
Year-to-date performance
686.98%
Rising
Drawdown
-16.40%
Marked drawdown
Position in the 52-week range
82% of range
Gross margin 17.8%, the company loses 110.5% of its revenue, ROIC -26.5%, ROE -34.5%.
Net margin
-110.46%
Negative
Sector -13.47%|S&P 13.40%
Gross margin
17.82%
Low
Return on equity (ROE)
-34.50%
Negative
Sector -17.71%|S&P 17.06%
Return on invested capital (ROIC)
-26.52%
Negative
Free cash flow margin (FCF)
-78.02%
Negative
Margin stability
245.9 pts
Very uneven
Revenue to net income
Growth
2.1/10Revenue up 29.2% over 1 year, 19.3% a year over 5.
Revenue (trailing 12 months)
2.5Md USD
Revenue growth (1y)
29.23%
Hyper-growth
Revenue growth (3y)
-89.83%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 31.0x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 17.4x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
95.0Md USD
Financial strength
5.8/10Cash covers 122.3% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-13.78%
Net cash
Cash
5.2Md USD
Cash / market cap
5.44%
Tight
Cash / total debt
122.27%
Net cash
Interest coverage
-48.8x
Stretched
Net debt
-942M USD
Equity
6.8Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 250.83 USD
- MM20229.34
- MM50196.67
- MM20093.58
- RSI 1459.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+27.26%
200-day average slope, 3 months
+102.95%
50-day average slope, 1 month
+39.06%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
6.48 % per day
Volatility change
-37.29%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -7.37 (19) | -7.38 (16) | 2 411 (17) | -2 720 (7) | -2 932 (16) |
| 2027 | -4.34 (20) | -4.19 (15) | 2 668 (21) | -1 629 (9) | -1 671 (17) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.6 | 6.6 | 47.2Md USD | 53.2x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 25.7 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.1 | 1.3 | 95.0Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | — | -2.1 % | 800.7 % |
